CDC/ACIP [to 23 Nov 2019]
Tuesday, November 19, 2019
CDC Updates EVALI Guidance for Health Care Providers as Flu Activity Increases Nationally
MMWR News Synopsis for Friday, November 22, 2019
Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥ 65 Years: Updated Recommendations of the Advisory Committee on Immunization Practices
CDC now recommends pneumococcal conjugate vaccine (PCV13) based on shared clinical decision making for adults 65 years or older who do not have an immunocompromising condition, cerebrospinal fluid (CSF) leak, or cochlear implant and who have not previously received PCV13. Due to decreasing rates of infection after several years of widespread vaccination CDC no longer recommends routine PCV13 use among all adults aged 65 years or older. Instead, older adults who have not received PCV13 and do not have an immunocompromising condition, CSF leak, or cochlear implant should discuss PCV13 vaccination with their vaccine providers to decide if PCV13 might be appropriate for them. Considerations may include likelihood of exposure due to traveling to or living in communities with higher rates of disease caused by vaccine strains and, if exposed, their risk of developing pneumococcal disease due to their underlying medical conditions. CDC continues to recommend PCV13 for adults, including older adults, who have an immunocompromising condition, CSF leak, or cochlear implant, as well as PPSV23 for all adults aged 65+ years.